The use of small animal models in basic and preclinical sciences constitutes an integral part
of testing new pharmaceutical agents prior to commercial translation to clinical practice …

2-Methoxyestradiol (2MeO-E2) is an endogenous metabolite of estrogen which was initially
considered to be inactive. During the last few decades it has been shown that 2MeO-E2 is a …

Sorafenib is the approved systemic drug of choice for advanced hepatocellular carcinoma
(HCC), but has demonstrated limited benefits because of drug resistance. 2 …

Methoxyestradiol (2ME 2), an estrogen hormone metabolite is a potential cancer
chemotherapeutic agent. Presently, it is an investigational drug under various phases of …

2-Methoxyestradiol is an active metabolite of 17β-estradiol in the human body. Various
publications have suggested that 2-methoxyestradiol possesses potent antitumor effects …

The endogenous steroid 2-methoxyestradiol (2-ME) is a metabolite of 17β-estradiol and its
biosynthesis is well established. Moreover, 2-ME is also biosynthesized from estrone. For …

Steroid sulfatase (STS) catalyzes the hydrolysis of steroid sulfates to estrones, the main
source of estrogens in tumors. Carbonic anhydrase II (CAII) is highly expressed in red blood …

A four-step route for the synthesis of 2-methoxyestradiol (5) starting from 17β-estradiol (1)
has been achieved with a 51% overall yield. The key step was the ruthenium-catalyzed …

An efficient and concise synthesis of 2-methoxyestradiol (4) from 17β-estradiol (1) has been
achieved in three synthetic steps with a 63.3% overall yield. The key step was the palladium …

A number of researchers in Korea have tried to set-up the production of radionuclides and
develop new radiopharmaceuticals for several decades. Thanks to their 60-year endeavor to …